← Back to Search

Monoclonal Antibodies

Trastuzumab Deruxtecan + Nivolumab for Esophageal Cancer

Phase 2
Recruiting
Led By Howard Safran, MD
Research Sponsored by Brown University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
HER2 overexpression defined by immunohistochemistry (IHC) 3+ or HER2 amplification by fluorescence in situ hybridization (FISH)
Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom with spermicide
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first dose of study treatment until time of cancer recurrence or death from any cause, whichever occurs first, maximum of 36 months
Awards & highlights

Study Summary

This trial is testing a combination of two drugs to see if it is safe and effective in treating esophagogastric adenocarcinoma.

Who is the study for?
This trial is for adults who've had surgery after chemoradiation for HER2+ esophageal or gastroesophageal junction cancer but didn't have a complete response. They must be 4-12 weeks post-surgery, with certain stages of disease pre-treatment, and agree to contraception if applicable. Excluded are those previously treated with similar drugs, having significant heart issues, other cancers within 3 years (some exceptions), uncontrolled infections, or severe allergies to study drugs.Check my eligibility
What is being tested?
The trial tests the safety and effectiveness of Trastuzumab Deruxtecan (Enhertu) combined with Nivolumab in patients who are disease-free post-trimodality treatment for HER2+ esophagogastric cancer. It's an open-label phase II study where all participants receive the drug combination for one year.See study design
What are the potential side effects?
Possible side effects include allergic reactions to medication components, immune-related effects like inflammation in organs due to Nivolumab, potential heart problems from Trastuzumab Deruxtecan, as well as general symptoms such as fatigue and digestive issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer shows high levels of HER2.
Select...
I am a man who can father children and will use a condom with spermicide.
Select...
I am post-menopausal or not pregnant and sexually active with a man who is not sterilized.
Select...
I had chemoradiation and surgery for esophageal cancer but still have some cancer cells.
Select...
It has been 4 to 12 weeks since my esophagus surgery.
Select...
I am fully active or can carry out light work.
Select...
My cancer originates from the esophagus, esophagogastric junction, or stomach.
Select...
I am 18 years old or older.
Select...
My cancer was at an early stage before receiving combined treatments.
Select...
My recent tests show my organs and bone marrow are functioning well.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first dose of study treatment until time of cancer recurrence or death from any cause, whichever occurs first, maximum of 36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and first dose of study treatment until time of cancer recurrence or death from any cause, whichever occurs first, maximum of 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of the addition of adjuvant trastuzumab deruxtecan with nivolumab for patients with esophagogastric cancer who have completed trimodality treatment
Secondary outcome measures
Disease-free survival with adjuvant trastuzumab deruxtecan & nivolumab after completion of trimodality treatment for HER2+ esophageal cancer.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Starting Trastuzumab Deruxtecan DoseExperimental Treatment2 Interventions
Trastuzumab deruxtecan, 6.4 mg/kg IV every 3 weeks for 17 doses (12 months)
Group II: Second Trastuzumab Deruxtecan Dose ReductionExperimental Treatment2 Interventions
Trastuzumab deruxtecan, 4.4 mg/kg IV every 3 weeks for 17 doses (12 months)
Group III: First Trastuzumab Deruxtecan Dose ReductionExperimental Treatment2 Interventions
Trastuzumab deruxtecan, 5.4 mg/kg IV every 3 weeks for 17 doses (12 months)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
2014
Completed Phase 3
~4750
Trastuzumab deruxtecan
2022
Completed Phase 2
~320

Find a Location

Who is running the clinical trial?

Brown UniversityLead Sponsor
454 Previous Clinical Trials
562,786 Total Patients Enrolled
AstraZenecaIndustry Sponsor
4,245 Previous Clinical Trials
288,529,223 Total Patients Enrolled
Howard Safran, MDPrincipal InvestigatorLifespan Cancer Institute
30 Previous Clinical Trials
908 Total Patients Enrolled

Media Library

Trastuzumab deruxtecan (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05480384 — Phase 2
Esophageal Cancer Research Study Groups: First Trastuzumab Deruxtecan Dose Reduction, Second Trastuzumab Deruxtecan Dose Reduction, Starting Trastuzumab Deruxtecan Dose
Esophageal Cancer Clinical Trial 2023: Trastuzumab deruxtecan Highlights & Side Effects. Trial Name: NCT05480384 — Phase 2
Trastuzumab deruxtecan (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05480384 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what degree does Trastuzumab deruxtecan pose a hazard to individuals?

"The safety of Trastuzumab deruxtecan was evaluated and given a score of 2 - signifying that there is clinical evidence supporting its safety but none proving efficacy."

Answered by AI

Is there currently an opportunity to join this experiment?

"As confirmed on clinicaltrials.gov, this medical research project is not accepting patients at the moment as it last updated its status on July 28th 2022. Nonetheless, there are 421 other trials that require enrollment currently active across various sites."

Answered by AI
~13 spots leftby Jan 2025